• Explore /
  • Poster
  • / Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.

Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.

Abstract Poster

Authors

Thierry Andre

Thierry Andre

Hopital Saint Antoine, Paris, France

Thierry Andre , Sara Lonardi , Ka Yeung Mark Wong , Michael Morse , Raymond S. McDermott , Andrew Graham Hill , Alain Hendlisz , Heinz-Josef Lenz , Joseph W. Leach , Rebecca Anne Moss , Z. Alexander Cao , Jean-Marie Ledeine , Emily Chan , Scott Kopetz , Michael J. Overman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT02060188

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3531)

DOI

10.1200/JCO.2017.35.15_suppl.3531

Abstract #

3531

Poster Bd #

154

Abstract Disclosures

Similar Posters

First Author: Michael J. Overman

First Author: Heinz-Josef Lenz

First Author: Michael J. Overman

First Author: Thierry Andre